Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Bukwang Pharmaceutical Co Ltd (Bukwang) is a pharmaceutical company that develops drugs and pharmaceutical products. The company’s pipeline product includes Lurasidone, JM-010, and SOL-804 for the indications of schizophrenia, bipolar disorder, Parkinson's disease, prostate cancer, solid tumors, and dementia. Bukwang also offers over-the-counter medicine, health functional food, and general medicine for various therapeutic areas. The company offers products in dosage forms such as solid dosage forms, ointments, liquid dosage forms, external liquid dosage forms, and injection dosage forms. It operates in Denmark, South Korea, Singapore, and Israel. Bukwang Pharmaceutical is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
7, Sangdo-Ro, Dongjak-Gu, Seoul, 06955
Website
www.bukwang.co.kr
Telephone
82 2 8288114
No of Employees
621
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
003000 (KRX)
Revenue (2024)
$117.5M
27.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
91.6%
(2024 vs 2023)
Market Cap*
$404.5M
Net Profit Margin (2024)
XYZ
93.4%
(2024 vs 2023)
* As of and is in US$
Bukwang Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Tavex Gel |
| Lurasidone: Schizophrenia, Bipolar Disorder | Alaxyl Granule |
| JM-010 (Contera): Parkinson's Disease Dyskinesia | Phazyme |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Bukwang Pharmaceutical Co Ltd | Daewoong Pharmaceutical Co Ltd | Whan In Pharm Co Ltd | Yungjin Pharm Co Ltd | Seoul Pharma Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Hwaseong | Seoul | Seoul | Cheongju |
| State/Province | Seoul | - | Seoul | Seoul | - |
| No. of Employees | 621 | 1,749 | 653 | 622 | 132 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jae Young Lee | Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer